Selected article for: "China Hubei province case and Hubei province"
Author: Kim, Sun Bean; Huh, Kyungmin; Heo, Jung Yeon; Joo, Eun-Jeong; Kim, Youn Jeong; Choi, Won Suk; Kim, Yae-Jean; Seo, Yu Bin; Yoon, Young Kyung; Ku, Nam Su; Jeong, Su Jin; Kim, Sung-Han; Peck, Kyong Ran; Yeom, Joon Sup
Title: Interim Guidelines on Antiviral Therapy for COVID-19
  • Cord-id: qqlkbs2p
  • Document date: 2020_5_19
    • ID: qqlkbs2p
    Snippet: Since the first case was reported in Wuhan, Hubei Province, China on December 12, 2019, Coronavirus disease 2019 (COVID-19) has spread widely to other countries since January 2020. As of April 16, 2020, 10635 confirmed cases have been reported, with 230 deaths in Korea. COVID-19 patients may be asymptomatic or show various clinical manifestations, including acute symptoms such as fever, fatigue, sore throat; pneumonia presenting as acute respiratory distress syndrome; and multiple organ failure.
    Document: Since the first case was reported in Wuhan, Hubei Province, China on December 12, 2019, Coronavirus disease 2019 (COVID-19) has spread widely to other countries since January 2020. As of April 16, 2020, 10635 confirmed cases have been reported, with 230 deaths in Korea. COVID-19 patients may be asymptomatic or show various clinical manifestations, including acute symptoms such as fever, fatigue, sore throat; pneumonia presenting as acute respiratory distress syndrome; and multiple organ failure. As COVID-19 has such varied clinical manifestations and case fatality rates, no standard antiviral therapy regimen has been established other than supportive therapy. In the present guideline, we aim to introduce potentially helpful antiviral and other drug therapies based on in vivo and in vitro research and clinical experiences from many countries.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and additional study: 1
    • action mechanism and load reduction: 1, 2
    • action mechanism and loading dose: 1, 2
    • action mechanism and long term exposure: 1, 2
    • action mechanism and lopinavir hydroxychloroquine: 1, 2, 3
    • action mechanism and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • action mechanism and low concentration: 1, 2, 3, 4
    • action mechanism and low concentration effective: 1
    • action mechanism and low mortality: 1
    • acute respiratory syndrome and administration dosage: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and liver dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and load reduction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and loading dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and local epidemiology: 1, 2, 3, 4, 5
    • acute respiratory syndrome and long term exposure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory syndrome and lopinavir hydroxychloroquine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low concentration effective: 1, 2